Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia once-monthly dosing may help improve treatment compliance PERSERIS is a first-line treatment option for...
Results from Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association's Virtual Scientific Sessions 2020 VASCEPA®, compared with placebo, significantly...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief...
Revenue of $13.1 million, Adjusted EBITDA of $4.5 million and cash from operations of $2.4 million Produced strong Vascepa prescription growth amid COVID-19 challenges: approximately 1,200...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 2020 financial results by press release at 6:30 a.m. Eastern Daylight Time on Thursday, November 5,...